Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
CA 2485216 A1 · Owner: Neuronova Ab · Inventors: Mercer, Alex; Patrone, Cesare; Wikstroem, Lilian
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates generally to methods of influencing central nervous system cells to produce progeny useful in the treatment of CNS disorders. More specifically, the invention includes methods of exposing a patient suffering from such a disorder to a reagent that modulates the proliferation migration, differentiation and survival of central nervous system cells via PACAP Maxadilan or VIP signaling. These methods are useful for reducing at least one symptom of the disorder.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 2, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 2, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 2, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.